Literature DB >> 25862464

Choice of Outcome Measure in an Economic Evaluation: A Potential Role for the Capability Approach.

Paula K Lorgelly1.   

Abstract

The last decade has seen a renewed interest in Sen's capability approach; health economists have been instrumental in leading much of this work. One particular stream of research is the application of the approach to outcome measurement. To date, there have been a dozen attempts (some combined) to operationalise the approach, and produce an outcome measure that offers a broader evaluative space than health-related quality-of-life measures. Applications have so far been confined to public health, physical, mental health and social care interventions, but the capability approach could be of benefit to evaluations of pharmacotherapies and other technologies. This paper provides an introduction to the capability approach, reviews the measures that are available for use in an economic evaluation, including their current applications, and then concludes with a discussion of a number of issues that require further consideration before the approach is adopted more widely to inform resource allocation decisions.

Mesh:

Year:  2015        PMID: 25862464     DOI: 10.1007/s40273-015-0275-x

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  35 in total

1.  Valuing the economic benefits of complex interventions: when maximising health is not sufficient.

Authors:  Katherine Payne; Marion McAllister; Linda M Davies
Journal:  Health Econ       Date:  2012-02-06       Impact factor: 3.046

Review 2.  Is economic evaluation in touch with society's health values?

Authors:  Joanna Coast
Journal:  BMJ       Date:  2004-11-20

3.  Welfarism, extra-welfarism and capability: the spread of ideas in health economics.

Authors:  Joanna Coast; Richard D Smith; Paula Lorgelly
Journal:  Soc Sci Med       Date:  2008-07-25       Impact factor: 4.634

4.  Long-term consequences of childhood ADHD on criminal activities.

Authors:  Jason Fletcher; Barbara Wolfe
Journal:  J Ment Health Policy Econ       Date:  2009-09

5.  Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder.

Authors:  Kristina Secnik; Andrine Swensen; Maureen J Lage
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.

Authors:  Karl Claxton; Steve Martin; Marta Soares; Nigel Rice; Eldon Spackman; Sebastian Hinde; Nancy Devlin; Peter C Smith; Mark Sculpher
Journal:  Health Technol Assess       Date:  2015-02       Impact factor: 4.014

7.  Best--worst scaling: What it can do for health care research and how to do it.

Authors:  Terry N Flynn; Jordan J Louviere; Tim J Peters; Joanna Coast
Journal:  J Health Econ       Date:  2006-05-16       Impact factor: 3.883

8.  Telemonitoring-based service redesign for the management of uncontrolled hypertension (HITS): cost and cost-effectiveness analysis of a randomised controlled trial.

Authors:  Andrew Stoddart; Janet Hanley; Sarah Wild; Claudia Pagliari; Mary Paterson; Steff Lewis; Aziz Sheikh; Ashma Krishan; Paul Padfield; Brian McKinstry
Journal:  BMJ Open       Date:  2013-05-28       Impact factor: 2.692

9.  Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.

Authors:  Sara Khor; Jaclyn Beca; Murray Krahn; David Hodgson; Linda Lee; Michael Crump; Karen E Bremner; Jin Luo; Muhammad Mamdani; Chaim M Bell; Carol Sawka; Scott Gavura; Terrence Sullivan; Maureen Trudeau; Stuart Peacock; Jeffrey S Hoch
Journal:  BMC Cancer       Date:  2014-08-12       Impact factor: 4.430

10.  Development of a supportive care measure for economic evaluation of end-of-life care using qualitative methods.

Authors:  Eileen J Sutton; Joanna Coast
Journal:  Palliat Med       Date:  2013-05-22       Impact factor: 4.762

View more
  11 in total

1.  An Investigation of the Overlap Between the ICECAP-A and Five Preference-Based Health-Related Quality of Life Instruments.

Authors:  Lidia Engel; Duncan Mortimer; Stirling Bryan; Scott A Lear; David G T Whitehurst
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

2.  From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.

Authors:  Matthijs Versteegh; Saskia Knies; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

Review 3.  Conceptualising 'Benefits Beyond Health' in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis.

Authors:  Lidia Engel; Stirling Bryan; David G T Whitehurst
Journal:  Pharmacoeconomics       Date:  2021-08-23       Impact factor: 4.981

4.  Economic Evaluation of Interventions for Children with Neurodevelopmental Disorders: Opportunities and Challenges.

Authors:  Ramesh Lamsal; Jennifer D Zwicker
Journal:  Appl Health Econ Health Policy       Date:  2017-12       Impact factor: 2.561

5.  Applications of the Capability Approach in the Health Field: A Literature Review.

Authors:  Paul Mark Mitchell; Tracy E Roberts; Pelham M Barton; Joanna Coast
Journal:  Soc Indic Res       Date:  2016-05-10

6.  Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities?

Authors:  Paul Mark Mitchell; Sridhar Venkatapuram; Jeff Richardson; Angelo Iezzi; Joanna Coast
Journal:  Pharmacoeconomics       Date:  2017-06       Impact factor: 4.981

Review 7.  EQ-5D and the EuroQol Group: Past, Present and Future.

Authors:  Nancy J Devlin; Richard Brooks
Journal:  Appl Health Econ Health Policy       Date:  2017-04       Impact factor: 2.561

8.  Raise the Bar, Not the Threshold Value: Meeting Patient Preferences for Palliative and End-of-Life Care.

Authors:  Nikki McCaffrey; Simon Eckermann
Journal:  Pharmacoecon Open       Date:  2018-06

9.  Adaptation and assessments of the Chinese version of the ICECAP-A measurement.

Authors:  Chengxiang Tang; Yao Xiong; Hongyan Wu; Judy Xu
Journal:  Health Qual Life Outcomes       Date:  2018-03-12       Impact factor: 3.186

10.  Evaluation as institution: a contractarian argument for needs-based economic evaluation.

Authors:  Wolf H Rogowski
Journal:  BMC Med Ethics       Date:  2018-06-13       Impact factor: 2.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.